Myriam Mendila, Dr.

Chief Scientific Officer (CSO)
Head R&D

Myriam joined CureVac from Novartis, Switzerland, where she served as Chief Medical Officer in the Oncology Business Unit with responsibility for the worldwide medical affairs function. In this role, she was a member of several governance boards including the Oncology Leadership Team (OLT), the Scientific Development Leadership Team (sDLT) and the Development Committee Novartis (DCN). In the past, Myriam has held different leadership positions of increasing responsibility within Global Medical Affairs, U.S. Medical Affairs, Global Product Development and Global Product Strategy at Roche/Genentech. Prior to that, she led Global Medical Affairs at Roche HQ in Basel.

Myriam Mendila holds an M.D. degree from the Medical School Hanover. She has research papers in journals including AIDS, The Lancet, the Journal of Clinical Oncology, Annals of Oncology and The Lancet Oncology.

Back to Executive Board